Clinical studies on treatment of acute cerebral infarction with Xueshuantong injection

Du Jin-hang; Ren Zai-fang; Shi Zai-xiang; Huang Li

doi:10.1007/BF02836348

Your Location：

Home >

Browse articles >

Clinical studies on treatment of acute cerebral infarction with Xueshuantong injection

Updated：2021-08-27

- Clinical studies on treatment of acute cerebral infarction with Xueshuantong injection
- Chinese Journal of Integrative Medicine Vol. 9, Issue 1, Pages: 21-24(2003)
- Affiliations：
  
  Japan Friendship Hospital,Beijing,China
- Author bio：
- Funds：
- DOI：10.1007/BF02836348
  CLC：
- Published：2003，
Scan for full text
Jin-hang, D., Zai-fang, R., Zai-xiang, S. et al. Clinical studies on treatment of acute cerebral infarction with Xueshuantong injection., Chin. J. Integr. Med. 9, 21–24 (2003). https://doi.org/10.1007/BF02836348

Du Jin-hang, Ren Zai-fang, Shi Zai-xiang, et al. Clinical studies on treatment of acute cerebral infarction with Xueshuantong injection. [J]. Chinese Journal of Integrative Medicine 9(1):21-24(2003)
Jin-hang, D., Zai-fang, R., Zai-xiang, S. et al. Clinical studies on treatment of acute cerebral infarction with Xueshuantong injection., Chin. J. Integr. Med. 9, 21–24 (2003). https://doi.org/10.1007/BF02836348 DOI：

Du Jin-hang, Ren Zai-fang, Shi Zai-xiang, et al. Clinical studies on treatment of acute cerebral infarction with Xueshuantong injection. [J]. Chinese Journal of Integrative Medicine 9(1):21-24(2003) DOI： 10.1007/BF02836348.

摘要

Objective: To observe the effect of Xueshuantong injection (XST

with its ingredient as Notoginseng saponin

on acute cerebral infarction (ACI) and on blood coagulation and fibrinolysis

so as to comprehensively analyse the mechanism of XST.Methods: Fifty ACI patients were randomly divided into 2 groups

and XST group (30 patients) was treated with XST

and the control group (20 patients) given low molecular dextrose

as well as low molecular heparin calcium. The course of treatment for both groups was 15 days. The changes of effective rate

score of neurologic impairment

tissuetype plasminogen activator (tPA)

inhibitor of plasminogen activator (PAI)

D-D dimmer

antithrombinIII (AT-III)

and fibrinogen (Fbg) were all observed.Results: The total effective rate of XST group was 73.33%

that of the control group 65. 00%. After the therapy

plasma level of tPA

ratio of tPA/PAI

and AT-III content were increased obviously

while the plasma level of PAI and D-D dimmer were decreased significantly (all P<0.01). But there was only insignificant difference between the 2 groups (P> 0.05).Conclusion: XST injection could be effective to ACI

the mechanism of which is probably related to improving the balance between plasminogen activator and its inhibitory factor

increasing the activity of fibrinolysin

inactivating thrombin

inhibiting platelet aggregation induced by thrombin

and decreasing blood coagulation.

Abstract

Objective: To observe the effect of Xueshuantong injection (XST

with its ingredient as Notoginseng saponin

on acute cerebral infarction (ACI) and on blood coagulation and fibrinolysis

so as to comprehensively analyse the mechanism of XST.Methods: Fifty ACI patients were randomly divided into 2 groups

and XST group (30 patients) was treated with XST

and the control group (20 patients) given low molecular dextrose

as well as low molecular heparin calcium. The course of treatment for both groups was 15 days. The changes of effective rate

score of neurologic impairment

tissuetype plasminogen activator (tPA)

inhibitor of plasminogen activator (PAI)

D-D dimmer

antithrombinIII (AT-III)

and fibrinogen (Fbg) were all observed.Results: The total effective rate of XST group was 73.33%

that of the control group 65. 00%. After the therapy

plasma level of tPA

ratio of tPA/PAI

and AT-III content were increased obviously

the mechanism of which is probably related to improving the balance between plasminogen activator and its inhibitory factor

increasing the activity of fibrinolysin

inactivating thrombin

inhibiting platelet aggregation induced by thrombin

and decreasing blood coagulation.

关键词

Xueshuantongacute cerebral infarctiontissue type plasminogenplasminogen inhibitorD-D dimmerantithrombin-IIIFibrinogen

Keywords

Xueshuantongacute cerebral infarctiontissue type plasminogenplasminogen inhibitorD-D dimmerantithrombin-IIIFibrinogen

references

SONG HB, MENG SQ, GAO QJ. Therapeutic effect of Notoginseng saponin injection in treating acute onset stage heart failure of cor pulmonale. Chin J Integ Trad West Med Emerg 1999; 6 (11): 507–509.

XIONG YH, PI ZJ, QIAN LZ, et al. Comparative observation of Notoginseng saponin and low molecule dextran in treating cerebral infarction. J Stroke Neurolog Dis 1998;5(3): 165–166.

Chinese Association of Neurology, Chinese Association of Neurosurgery. Main diagnostic points of various cerebrovascular diseases. Chin J Neurology 1996; 29(6): 379–381.

Adams H, Bendixen BH, Kapelle LT, et al. Classification of subtype of acute ischemic stroke. Stroke 1993;24(1): 99–101.

WANG XD. Suggestions on clinical study of cerebral stroke. Chin J Neurolog Psychia 1988;21(1): 57–60.

CHEN DR, SHI YM, TIAN GQ, et al. Comparative study of Ligustrazine and low molecule dextran in treating acute cerebral infarction. Chin J Integra Tradi West Med (Chin) 1992; 12(2): 71–73.

TAN MX, WEI GZ, WANG XD. Suggestions on the treatment of acute ischemic cerebral stroke patients. Chin J Neurolog Psychiatr 1998;24(5): 315–316.

SHI XH, HAN CY, TIAN SL, et al. Study on plasma tPA, PAI activity of cerebral thrombosis patients. Chin J Neurolog Psychiatr 1992;25: 260.

Feinberg WM, Bruck DC, Ring ME, et al. Hemostatic markers in acute stroke. Stroke 1989;20(2): 592–594.

GAO YQ, XIE XF, WANG XF, et al. The clinical significance of plasma D-dipoid determination of acute cerebrovascular diseases. J Clin Neurolog 1996; 9(4): 209.

ZHANG JL, HE ML. Effect of before and after intravenous thrombolytic treatment on blood coagulation and fibrinolytic system. J Stroke Neurolog Dis 1999; 16(1): 35–36.

LU J. Analysis of preliminary determination on anti-thrombin-III and fibrinogen of acute cerebrovascular disease. Chin J Neurolog 1989;22: 205–206.

MA X. Observation on fibrinogen molecule reactivity of ischemic cardio-cerebrovascular disease. Chin J Hematolog 1996; 17(3): 135.

Willhemsen L. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501.

MA BS, CHANG JM. General survey on integrative Chinese and western medicine in treating cerebrovascular disease, Chin J Chin Wes Med Emerg 1995; 2(6): 286–287.

LI LX, WANG ZC, LI YY, et al. Protection of Notoginseng saponin D1 on rabbit acute ischemia. Chin Pharmacolog Acad J 1991;7(5): 350–353.

FULL TEXT LINK

More>

Views

342

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Study on the correlation of tongue manifestation with fibrinogen and neutrophil in acute cerebral infarction patients

Study on the changes of thrombosis-associated factors in patients with coronary heart disease of turbidity-phlegm blocking syndrome

Effect of Xuesaitong soft capsule on hemorrheology and in auxiliarily treating patients with acute cerebral infarction

Effect of the principle of activating blood circulation to break stasis on GMP-140 and D2 dimer in patients with acute cerebral infarction

Effect of Tongxinluo capsule on plasma endothelin, calcitonin gene-related peptide and nitrogen oxide of acute cerebral infarction patients

Related Author

No data

Related Institution

Key Laboratory of Neurodegenerative Diseases (Capital Medical University), Ministry of Education

Cerebrovascular Diseases Research Institute, Xuanwu Hospital of Capital Medical University

Department of Neurology, Xuanwu Hospital of Capital Medical University

Traditional Chinese Medicine College of Xinjiang Medical University, Urumiqi

The Second People’s Hospital of Liaocheng

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰